Tumor-associated trypsin inhibitor in patients with endometrial cancer.
OBJECTIVE
The aim of the study was to look for prognostic factors of metastasis or recurrence in patients with endometrial cancer.


METHODS
Tumor-associated trypsin inhibitor (TATI) concentrations were measured in serum of 317 patients with endometrial cancer. The assay was done 7 times in each patient, from the moment of diagnosis until the start of follow-up after the completion of treatment. Observation of patients after treatment lasted from 0 to 16 years.


RESULTS
The TATI levels in patients with adverse prognostic factors accumulated in the first 3 assays and then decreased to zero. Mean TATI concentrations were significantly higher in patients with clinically advanced disease (stage IIIB) than patients at stage I (Kruskal-Wallis p = 0.0446). An increase in the concentration by more than 10.6% in the first 3 assays was significantly correlated with disease relapse (Mann-Whitney Z = -6.06653, p = 0.00000) and local or distant recurrence (Mann-Whitney Z = -4.97475, p = 0.000001). A significant increase in the TATI level in the first 3 tests also occurred in patients who died during the study period (Kruskal Wallis p&lt;0.001). In our series of patients with endometrial cancer, TATI proved to be a sensitive indicator of disease recurrence and distant metastasis, with a sensitivity of 84.4% and 75.7%, respectively.


CONCLUSIONS
TATI seems to behave as a prognostic factor in certain subgroups of patients with endometrial cancer.
Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw - Poland.|Faculty of Health Sciences Gynecological and Obstetrics Department Medical University, Warsaw - Poland.
Barbara
B
Kozakiewicz
Institute of Psychiatry and Neurology, Warsaw - Poland.
Małgorzata
M
Chądzyńska
Faculty of Health Sciences Gynecological and Obstetrics Department Medical University, Warsaw - Poland.
Ewa
E
Dmoch-Gajzlerska
Faculty of Health Sciences Gynecological and Obstetrics Department Medical University, Warsaw - Poland.
Małgorzata
M
Stefaniak
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D016889:Endometrial Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D012680:Sensitivity and Specificity; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*
D014408:Biomarkers, Tumor; D014359:Trypsin Inhibitor, Kazal Pancreatic